Research · Source update
Foundayo weight-loss findings across menopause stages
Source context: Read the linked original research or registry entry for study status and limitations.
Lilly analyzed female participants in ATTAIN studies by menopause stage. MyDosePro reviewed the originating organization's statement to identify the reported results and their limitations.
What prompted this update?
Lilly analyzed female participants in ATTAIN studies by menopause stage. MyDosePro reviewed the originating organization's statement to identify the reported results and their limitations. The originating source is Lilly ATTAIN menopause subgroup analysis, dated 2026-06-07.
What did the source report?
The company reported substantial weight loss across peri- and post-menopausal study subgroups. The sponsor described weight reduction across menopause subgroups, with more than 14% reported for some peri- and postmenopausal participants.
How should the results be interpreted?
This is a post-hoc subgroup analysis; menopause categories do not independently prove different treatment effects. Post-hoc subgroup analyses should not be used to promise different results based solely on menopausal status.
What remains uncertain?
These findings apply to the specific study, date, population, product and endpoint described in the primary source. The source may be a sponsor announcement before full peer-reviewed publication. Check the original document and current regulatory status before drawing conclusions about personal treatment. Where a study or subgroup result was first released by a manufacturer, it should not be treated as independent confirmation of every claim; compare the full protocol, population, endpoints and subsequent publications.
What does this mean for patients?
Subgroups provide context, not personalized predictions. Treatment decisions depend on approved labeling, individual medical circumstances, availability and actual insurance benefits. MyDosePro offers educational context, not individualized prescribing or coverage confirmation.
The bottom line
Subgroups provide context, not personalized predictions.
Written and published by MyDosePro as an educational explanation of publicly available evidence. The linked primary source is dated 2026-06-07. We identify trial registrations separately from published results and do not provide individual prescribing advice.
Primary sourceLilly ATTAIN menopause subgroup analysis ↗
Source event or update: 2026-06-07. Our interpretation is educational and does not replace medical or insurance advice.